Skip to main content

Equibles does not estimate personal net worth.

Get an email with a short summary when Trevi Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.

Get TRVI alerts

About James Cassella

Trevi Therapeutics, Inc. reported in an 8-K filed October 1, 2024 that James Cassella resigned as member of the Board of Directors, effective September 30, 2024. Trevi Therapeutics, Inc. reported in an 8-K filed October 1, 2024 that James Cassella was appointed Chief Development Officer, effective September 30, 2024. The proxy statement of Trevi Therapeutics, Inc. reports total compensation of $1,637,220 for James Cassella in fiscal 2025, including a base salary of $488,270. Disclosed compensation is on record for 3 fiscal years. James Cassella has spoken on 1 earnings call and 2 other investor events across 1 company, most recently for Trevi Therapeutics, Inc. on September 16, 2026. Trevi Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Trevi Therapeutics, Inc. includes Christopher Galletta (Chief Accounting Officer), Anne VanLent (Board Member), Dominick C. Colangelo (Board Member) and 2 others.

“In connection with his appointment as Chief Development Officer of the Company, on September 27, 2024, Dr. Cassella resigned from his position as a member of the Board of Directors of the Company, effective as of September 30, 2024.”
Trevi Therapeutics, Inc. Form 8-K, filed October 1, 2024 · Read the filing
“On September 30, 2024, Trevi Therapeutics, Inc. (the "Company") announced that James Cassella, Ph.D., had agreed to join the Company as its Chief Development Officer.”
Trevi Therapeutics, Inc. Form 8-K, filed October 1, 2024 · Read the filing

James Cassella on recent calls

“So we have good experience with our IPF population. We've run two studies to date that were enabling us to start the Phase III program. The first was a crossover study, the canal study.”
Other, Morgan Stanley 24th Annual Global Healthcare Conference ·
“And Rwana, in terms of the trial, lake trial, and the SSRE, the basis of that trial is from our river study, the findings that we had in RCC and based on what we saw in our coral program.”
Other, Trevi Therapeutics, Inc. Q2 FY2026 Earnings Call ·
“And I think the key is that we have very, very solid data going into the Phase 3 program. We've conducted two trials in IPF-related COF to date, our canal and our CORAL trial.”
Other, Leerink Partners 2026 Global Healthcare Conference ·

Affiliation history

Company network

Leadership on record at Trevi Therapeutics, Inc.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 Trevi Therapeutics, Inc. (TRVI) $488,270 $1,637,220
2024 Trevi Therapeutics, Inc. (TRVI) $120,000 $1,441,119
2023 Trevi Therapeutics, Inc. (TRVI) — —

Recent activity